leuprolide
Overview
Leuprolide (Lupron) is a synthetic GnRH (gonadotropin-releasing hormone) agonist that, on continuous administration, suppresses LH and FSH secretion from the pituitary, resulting in castrate levels of testosterone. It is a cornerstone of androgen-deprivation therapy (ADT) for prostate cancer and is also used in other hormone-sensitive conditions (endometriosis, precocious puberty).
Evidence in the corpus
- Leuprolide was identified as one of the prior treatments extracted by the MSK-CHORD NLP pipeline from clinical notes across 3,211 prostate cancer (PRAD) patients in the MSK-CHORD dataset. It was captured as part of the treatment-annotation component used to define prior systemic therapy exposure for the multimodal survival modeling and post-treatment genomic enrichment analyses PMID:39506116.
Resistance mechanisms
- Not directly characterized in the corpus; androgen-receptor (AR) alterations and TP53 mutations are enriched in prostate cancer patients with prior systemic therapy (including ADT) in MSK-CHORD PMID:39506116.
Cancer types (linked)
- PRAD — prostate adenocarcinoma (ADT backbone; prior therapy annotation in MSK-CHORD)
Sources
- PMID:39506116 — Jee et al. 2024, Nature. MSK-CHORD real-world data integration; leuprolide as NLP-extracted prior treatment in the prostate cancer cohort.
This page was processed by crosslinker on 2026-04-30.